Paloma Partners’s Stoke Therapeutics STOK Stock Holding History

Paloma Partners’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,150	Closed	-$242K	–	2428
2020 Q2	$242K	Buy	+10,150	New	+$241K	﹤0.01%	1589

Other funds holding STOK

ALSV

ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Paloma Partners's STOK Position: Q3 2020 in Review

Paloma Partners sold out of Stoke Therapeutics (STOK) in Q3 2020, closing a stake of 10,150 shares — an estimated $242K sold.

Paloma Partners first reported a position in STOK in Q2 2020 and held it in 1 quarter. The position peaked at $242K in Q2 2020. 88 funds tracked by Wall St. Rank hold STOK as of Q3 2020.

Paloma Partners reported no remaining Stoke Therapeutics position as of Q3 2020 after selling out during the quarter.
Paloma Partners sold 10,150 Stoke Therapeutics shares in Q3 2020, an estimated $242K.
Paloma Partners first reported a position in Stoke Therapeutics in Q2 2020 and held it in 1 quarter.
Paloma Partners's Stoke Therapeutics position peaked at $242K in Q2 2020.
88 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.